solomo.ai

Tarsons Products Ltd (TARSONS) — shareholding pattern, promoter holding, financials and share price

About Tarsons Products Ltd (TARSONS)

Tarsons Products Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as TARSONS and on the BSE under scrip code 543399. Its ISIN is INE144Z01023.

Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals [1]

Tarsons Products Limited is an Indian labware manufacturer designing, developing, manufacturing and marketing consumables, reusables and benchtop instruments used by research organisations, academia, pharma, CROs, diagnostics and hospitals; the company operates multiple automated clean-room plants, sells 2,000+ SKUs across 350 product segments, and serves domestic and export customers through a pan-India distributor network and 45+ overseas partners.

Tarsons reported steady top-line growth in Q3FY26 with consolidated revenue growing 12.8% year-on-year and consolidated EBITDA increasing 6.3% to INR 31.5 crore; however, reported PAT is depressed due to accelerated depreciation and higher finance costs from partial capitalization of new facilities at Panchla and Amta, while adjusted cash PAT grew strongly, indicating cash-generative operations.

Listed peers in Medical Equipment & Supplies: Fischer Medical Ventures Ltd, Q-Line Biotech Ltd, Laxmi Dental Ltd, OSEL Devices Ltd, Fabtech Technologies Ltd, Vasa Denticity Ltd.

Valuation & Returns

10 Jul 2026

At ₹304.55 a share on 10 Jul 2026, Tarsons Products Ltd (TARSONS) was valued at a price-to-earnings ratio of 113.16x against an industry P/E of 44.11x and a price-to-book of 2.57x on a book value of ₹118.45 per share as of Mar 2025. Solomo computes return on equity of 2.27% and return on capital employed of 4.59% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
113.16x
Industry P/E
44.11x
P/B
2.57x
EPS (TTM)
₹2.69
Book value / share
₹118.45
ROE
2.27%
ROCE
4.59%
ROA
1.33%
Debt / equity
0.54x
Dividend yield
0%
EBITDA margin
33.37%
52-week range
₹164.15 – ₹405.3

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Tarsons Products Ltd (TARSONS) reported revenue of ₹423 crore, net profit of ₹14 crore and earnings per share of ₹2.69. That compares with revenue of ₹392 crore and net profit of ₹30 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹120.93 crore and net profit ₹4.18 crore (consolidated).

Consolidated annual results for Tarsons Products Ltd (TARSONS), Mar 2021 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2021Mar 2022Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)229301296392423
Net profit (₹ cr)69101433014
EPS (₹)3,583.2518.928.015.62.69
Compound annual growth for Tarsons Products Ltd (TARSONS). Stock price CAGR is price return and excludes dividends.
Measure5Y3Y1Y
Sales growth12.30%1.46%32.40%
Profit growth1.06%-24.85%-30.18%
Stock price CAGR--21%-22%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 47.3% of Tarsons Products Ltd (TARSONS) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.16% and domestic institutional investors (DII) hold 0.1%. Market capitalisation was ₹1,620 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2021.

Largest disclosed public shareholders in Jun 2026: CLEAR VISION INVESTMENT HOLDINGS PTE LIMITED 23.42%, GRACIOUS ADVISORS LLP 3.15%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202647.3%-0.16%0.1%52.7%
Mar 202647.3%-0.87%0.19%52.7%
Dec 202547.3%-2.47%0%52.7%
Sep 202547.31%-5.82%0.08%52.69%
Jun 202547.31%-9.14%0.04%52.69%
Mar 202547.31%-9.52%0.29%52.69%
Dec 202447.31%-7.51%0.5%52.69%
Sep 202447.31%-8.04%0.21%52.69%
Every quarter since Dec 2021 Filing data, not investment advice.